Sotabase

Career

· Co-President, Co-Founder, Computational Biology at Berkeley2025–

Publications (19)

Osteoporotic Fractures
PharmacoEconomics (Auckland) · 2012
97
cited
Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing–remitting multiple sclerosis
Current Medical Research and Opinion · 2018
70
cited
Quantitation of ovine cytokine mRNA by real-time RT-PCR.
JIM - Journal of Immunological Methods · 2006
51
cited
Human plasma contains a soluble form of CD86 which is present at elevated levels in some leukaemia patients
Leukemia · 2002
44
cited
Changing epidemiology of meningococcal disease in Europe from the mid-20th to the early 21st Century
Expert Review of Vaccines · 2011
38
cited
Identification of an S-adenosylhomocysteine hydrolase-like transcript induced during dendritic cell differentiation
Immunogenetics · 2002
34
cited
Pregabalin, the lidocaine plaster and duloxetine in patients with refractory neuropathic pain: a systematic review
BMC Neurology · 2010
26
cited
Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
Applied Health Economics and Health Policy · 2019
15
cited
The Preparation and Biological Activity of Lactam-Based, Non-Steroidal, Inhibitors of Human Type-1 Steroid 5α-Reductase.
2010
2
cited
Discontinuation of Disease-modifying Treatments in Relapsing-remitting Multiple Sclerosis – A Systematic Literature Review of Observational Studies
European Neurological Review · 2019
1
cited
PND28 - A BUDGET IMPACT ANALYSIS OF CLADRIBINE TABLETS VERSUS ALTERNATIVE HIGH EFFICACY TREATMENTS FOR RELAPSING MULTIPLE SCLEROSIS (RMS) IN THE UNITED KINGDOM.
Value in Health · 2018
1
cited
PNS62 Project Orbis/Access Consortium - Are Quicker Regulatory Approvals Leading to Faster Reimbursement?
2021
1
cited
Correction to: Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
Applied Health Economics and Health Policy · 2020
EVIDENCE PROVIDED BY NON-RANDOMISED TRIALS IS NOT CONCLUSIVE ON THE EFFICACY OF 2ND LINE TREATMENTS IN PATIENTS WITH METASTATIC HORMONE REFRACTORY PROSTATE CANCER (MHRPC)
2010
OP20 Has The New HST Process Improved The Recommendation Chance In England?
International Journal of Technology Assessment in Health Care · 2019
PCN12 EFFICACY OF SECOND LINE TREATMENTS IN PATIENTS WITH METASTATIC HORMONE REFRACTORY PROSTATE CANCER (MHRPC) IS NOT DEMONSTRATED BY PUBLISHED EVIDENCE FROM NONRANDOMIZED TRIALS
2010
PND64 - COST-EFFECTIVENESS OF CLADRIBINE TABLETS FOR TREATMENT OF RRMS IN THE NETHERLANDS
Value in Health · 2018
PND71 - A COST MINIMISATION ANALYSIS OF CLADRIBINE TABLETS VERSUS ALTERNATIVE HIGH EFFICACY TREATMENTS FOR RELAPSING MULTIPLE SCLEROSIS (RMS) IN THE UNIED KINGDOM.
Value in Health · 2018
PP11 Would A Highly Specialized Technology Be Approved In England Under The New NICE Guidance?
International Journal of Technology Assessment in Health Care · 2018
Sotabase
Saket Budhia | Researcher Profile | Sotabase | Sotabase